

University of Groningen

## Diagnostic and therapeutic challenges in inflammatory eye diseases

Wieringa, Wietse Grieco

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2019

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Wieringa, W. G. (2019). *Diagnostic and therapeutic challenges in inflammatory eye diseases*. [Thesis fully internal (DIV), University of Groningen].

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# 6

## PHYSICAL AND PSYCHOSOCIAL HEALTH IN PEDIATRIC UVEITIS PATIENTS

### Authors:

Wietse G. Wieringa<sup>1</sup>,  
Rosanne van Berkel<sup>2</sup>,  
Leonoor I. Los<sup>1,3</sup>,  
Otto T.H.M. Lelieveld<sup>4</sup>,  
Wineke Armbrust<sup>2</sup>

### Affiliations of authors:

University Medical Center Groningen, University of Groningen, Department of Ophthalmology<sup>1</sup> and -Beatrix children's hospital department of children's rheumatology and immunology<sup>2</sup>, P. O. Box 30001, 9700 RB Groningen, the Netherlands.

W.J. Kolff Institute<sup>3</sup>, Graduate School of Medical Sciences, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands

Center of Rehabilitation<sup>4</sup>, University of Groningen, University Medical Center Groningen

*Submitted*

## ABSTRACT

**Background:** To investigate the possible associations between childhood uveitis and cardio-respiratory fitness, physical activity, health related quality of life and fatigue.

**Methods:** Cross-sectional analysis of 23 patients with non-infectious uveitis, aged 8-18 years. BMI, exercise capacity, muscle strength and physical activity were measured. Health-related quality of life and fatigue were assessed.

**Results:** Twenty-three patients were included. Children with uveitis had a higher bodyweight and body mass index when compared to healthy children. Patients with juvenile idiopathic arthritis (JIA)-associated uveitis had a significantly higher BMI than patients with idiopathic uveitis. Children with uveitis had lower cardio-respiratory fitness and they were less physically active when compared to their healthy peers, but they experienced a normal quality of life and normal fatigue. Parents of children with uveitis reported a lower quality of life and more fatigue for their children than parents of healthy children.

**Conclusion:** Our study indicates that children with non-infectious uveitis are at risk of developing lower physical and psychosocial health. We recommend that investigation and treatment of these aspects should be part of a multidisciplinary treatment approach in children with non-infectious uveitis.

## BACKGROUND

Uveitis is an inflammatory disorder of the eye, involving the uveal tract. In the western world the prevalence of pediatric uveitis is 30/100,000 and children account for 5-10% of the total uveitis population<sup>1</sup>. Uveitis may be caused by an infection, may be associated with a systemic auto-immune disease or may occur as an isolated auto-immune reaction without a known underlying cause<sup>2</sup>. In the developed countries, 87 – 89 % of the pediatric uveitis cases are non-infectious and the majority (41.5%) is related to juvenile idiopathic arthritis (JIA)<sup>1,3</sup>.

Patients with auto-immune diseases are more physically inactive compared to the general population<sup>4</sup>. Also, aerobic fitness in children with different types of chronic conditions is reduced and they report more fatigue<sup>5-7</sup>. In juvenile idiopathic arthritis (JIA), children are also found to be less physically active and have reduced physical fitness levels<sup>8</sup> which does not restore after remission has been reached<sup>9,10</sup>. The causes of these persistent impairments of physical fitness and physical activity are not known, but it has been suggested that a combination of disease-related factors, treatment (e.g., medication), hypo-activity, and deconditioning could be involved<sup>5,11,12</sup>.

The pathophysiology of non-infectious uveitis has not exactly been revealed<sup>13</sup>. It is not clear whether the inflammation in this “isolated uveitis” is really limited to the eye or may extend itself systemically<sup>14-20</sup>. A number of biomarkers have been identified in JIA-uveitis<sup>20</sup> and in auto-immune uveitis<sup>13</sup>. In oligoarticular and polyarticular rheumatoid factor negative JIA, an elevated erythrocyte sedimentation rate has been confirmed as a predictor of uveitis<sup>21,22</sup>. Also, in JIA-uveitis a lower level of cytokine IL-29 in aqueous humor (AqH) has been identified as a potential biomarker for uveitis<sup>20</sup>. In children with autoimmune uveitis, an increase in two pro-inflammatory S100 protein subtypes (S100A8/A9 and S100A12) levels in both serum and AqH has been reported<sup>23</sup>. And, in both idiopathic and JIA-uveitis a number of genetic predispositions have been found<sup>13,24</sup>.

Systemic treatment in children with idiopathic uveitis who do not respond sufficiently to topical therapy is comparable to that used in JIA. The first line of treatment in pediatric uveitis are local corticosteroids. If local corticosteroids are insufficient, a switch towards steroid sparing immunosuppressive therapy will be made in most cases. Sometimes local injections with corticosteroids can be considered. Systemic prednisone is started in case of severe uveitis and is given peri-operatively in case of intraocular surgery.

Because systemic inflammation can contribute to arteriosclerosis<sup>15-17</sup>, there is concern that children with inflammatory disease are at higher risk for cardiovascular diseases. In addition to the inflammation itself, systemic

corticosteroids have a negative impact on the cardiovascular risk profile. Well-known side effects are increased bodyweight, hypertension, and accelerated arteriosclerosis <sup>25</sup>.

In the literature, information on the physical and psychosocial health of children with uveitis is scarce <sup>26–28</sup>. A recent study on the quality of life (QoL) in children with JIA showed that children with uveitis had poorer vision-related QoL and function when compared to those without uveitis <sup>29</sup>. Some studies on health related (HR) QoL in adult uveitis patients found a decreased HR-QoL compared to the general population<sup>30, 31</sup>, whereas one study observed that HR-QoL in adults with JIA-uveitis was not decreased <sup>32</sup>. However, the use of systemic immunomodulatory treatment or the presence of co-morbidity other than uveitis, did negatively influence general HR-QoL scores in adult uveitis patients <sup>32,33</sup>. Also, in adolescents with non-infectious uveitis despite quiescence of disease and good visual function, certain factors, such as a high number of recurrences, chronicity of the uveitis and fear of blindness were correlated with a decreased HR-QoL <sup>34, 35</sup>.

In adults, fatigue has been shown to be a barrier for being physically active <sup>36</sup>. Fatigue is highly present in patients with JIA and is related to many factors including physical activity, physical fitness and HR-QoL of which cause and effect are not exactly known <sup>37</sup>. Also, in our clinical experience, fatigue is often reported by children with uveitis or by their parents. Therefore, uveitis may have a large impact on a child's life and can alter their QoL <sup>26, 27, 34</sup>.

To optimize treatment for children with uveitis it is of great importance to get insight in risk factors that have a negative impact on physical and psychosocial health. Regarding the possible negative effects of uveitis, we therefore studied levels of cardio-respiratory fitness, physical activity, muscle strength, health-related quality of life and fatigue in pediatric non-infectious uveitis patients.

## PATIENTS AND METHODS

The Medical Ethical Committee of the University Medical Center of Groningen (UMCG) approved the conduction of the study. Patients were included from the departments of children's rheumatology and ophthalmology of the UMCG (the Netherlands) from July till December 2014. Patients aged 8-18 years, known with idiopathic or JIA-associated uveitis were eligible for this study. Patients with infectious uveitis were not included. Patients with co-morbidities, not related to the uveitis, that could influence the outcome of the exercise test, like pulmonary or cardiac diseases, were excluded from the study. All investigations were carried out at one moment following the regular visit. Informed consent was obtained from the parents and from the child if the child was  $\geq 12$  years old.

## Patient characteristics

Information regarding patient characteristics (gender, age), disease characteristics (location of the uveitis, etiology, time since diagnosis, disease status), current treatment (medication, dose, route of administration), complications, and surgery was retrospectively gathered by consulting the medical charts of the patients. Median duration of active disease was recorded. Active disease was defined as observed cells in the anterior chamber or in the vitreous<sup>38</sup>. The diagnosis of posterior and panuveitis was made by fundoscopy and in some cases fluorescein angiography (FA) was performed.

Remission on medication was defined as an observable inactive disease in the affected eye for longer than 3 months without the use of systemic corticosteroids or local steroid injections (subtenon or subconjunctival)<sup>38</sup>. During this period, local steroid medication such as eye drops or ointment were allowed in a maintenance dosage of maximum of 4 times a day.

Patients were examined by an ophthalmologist to determine the activity of the uveitis. The visual acuity was measured with a Snellen chart and was converted to LogMAR-acuity for calculation and statistical purposes<sup>38, 39</sup>. Blindness was defined as a visual acuity less than 0.01 (or LogMAR > 1.3) or a visual field  $\leq 10^\circ$ <sup>40</sup>. Visual impairment was defined as a visual acuity  $\geq 0.05$  (LogMAR  $\leq 1.30$ ) and < 0.3 (LogMAR > 0.50)<sup>40</sup>.

Disease activity of JIA was scored on a 0-10 Physician Global Assessment (PGA) scale by a physician. Height and bodyweight were measured and body mass index (BMI = bodyweight(kg)/height<sup>2</sup> (m)) was calculated. These measurements were compared with the reference values of Dutch children<sup>41</sup>. Overweight was defined as  $\geq 1$ SD above the mean reference BMI and obesity as >2SD above the mean reference BMI<sup>42</sup>.

## Physical fitness

Physical fitness was assessed by measuring exercise capacity and muscle strength. Exercise capacity was measured with a cardiopulmonary exercise test using an electronically braked cycle ergometer, and was expressed by peak oxygen consumption ( $VO_{2peak}$ ) and peak work rate ( $W_{peak}$ ). We used a ramp version of the Godfrey protocol<sup>43</sup> in which the work rate increased gradually over time with 10, 15 or 20 Watt/min depending on the body height of the patient, as described by Bongers et al<sup>44</sup>. All patients were verbally encouraged to cycle until exhaustion. Maximal exertion was defined as a heart rate of > 180 beats per minute and a respiratory exchange ratio of more than 1.0<sup>44</sup>. The absolute values obtained during the test were compared with the reference values of healthy Dutch children<sup>44</sup>.  $VO_{2peak}$  - and  $W_{peak}$  per kg bodyweight were calculated and these relative values were also compared with the reference values<sup>44</sup>.

General muscle function was assessed by manual muscle testing using the scale of the Medical Research Council (MRC). This scale ranges from 0 till 5, in which 0 means no muscle contraction and 5 means normal muscle power<sup>45</sup>. Isometric muscle strength of four muscle groups was assessed bilaterally by hand-held dynamometry (HHD): the biceps, triceps, iliopsoas, and quadriceps muscles. The assessed values were converted to a total z-score of the four muscle groups and compared with the reference values of healthy children<sup>46</sup>.

### Physical activity

Physical activity (PA) was subsequently measured by an accelerometer (Actical, Philips respirionics). The accelerometer was given on the day of the regular visit and research measurements. The Actical measures accelerations in any plane of movement which are translated into activity counts as a reflection of physical activity. Counts were summed in 1-minute periods. Cut-off points were used to categorize activities as sedentary, light physical activity (LPA), and moderate-to-vigorous physical activity (MVPA)<sup>47</sup>. Patients were instructed to wear the accelerometer during 7 days, for all hours except during sleep and wet-activities (showering, swimming). Patients were also asked to record their physical activities in a diary during the same 7 days as they were wearing the accelerometer. In the diary, patients scored their dominant activity of each 15 minute period of every 24 hours of the day. The parents were allowed to help the child with filling out the diary<sup>48</sup>. Patients were asked to register in the diary at which moment they put the accelerometer on and off. Because non-wearing time of the accelerometer can be mistakenly categorized into sedentary activity, we corrected non-wearing time with the information provided in the activity diary. Patients were included in the analysis if they had minimally 4 valid days of wearing the accelerometer. A valid day was defined as a wearing time of minimally 8 hours on a weekday or minimally 6 hours on a weekend day. Mean daily counts were determined by the sum of the total daily counts divided by the number of valid days. The mean amount of time spent in the four different categories of physical activity per day was compared to the values of healthy Canadian youth<sup>49</sup>.

### Functional ability

Functional ability was assessed by using the Child Health Assessment Questionnaire (CHAQ38). Functional ability was expressed in the disability index (DI) which was calculated as the mean of the maximum scores of all domains. A higher score suggests more disability. The DI of the patients was compared to the DI of healthy Dutch children<sup>50,51</sup>.

### Health related quality of life

Health related quality of life (HR-QoL) was evaluated with the Pediatric Quality of Life Inventatory (PedsQL 4.0). The PedsQL measures HR-QoL in four domains:

physical, emotional, social and school functioning<sup>52</sup>. The questionnaire consists of a child self-report and a parent proxy report part and was completed by the child and the parent. A higher score (range 0-100) represents a higher quality of life. The scores of the patients were compared to the scores of healthy children<sup>52, 53</sup>.

## Fatigue

The level of fatigue in the patients was measured by the PedsQL Multidimensional Fatigue Scale, which measured fatigue in three domains: general fatigue, sleep/rest fatigue and cognitive fatigue<sup>53</sup>. The questionnaire consists of a child self-report and a parent proxy report part and was completed by the child and the parent. A higher score (range 0-100) indicates less fatigue. The scores of the patients were compared to the scores of healthy children<sup>52, 54</sup>.

## Statistical analysis

Statistical analyses were performed by using SPSS software (version 22). Descriptive statistics were used to present mean and standard deviation (SD) or median and range if data were abnormally distributed. The variables of the children were compared to the reference values of healthy children. Z-scores were calculated for age and gender dependent outcome measures as length, weight, BMI, peak oxygen consumption, peak work rate, and muscle strength. A z-score represents the amount of standard deviations the value differs from the age and gender specific reference value. A z-score above 0 means that the value measured in the study group is higher than in the reference group. A z-score below 0 is the other way around. The one sample t-test was used to compare the normally distributed outcomes of the patients with healthy controls, in case of abnormal distribution of the outcome parameters the one-sample Wilcoxon Signed Rank Test was used. To examine the possible relations between the outcome measurements, we analysed which measurements were correlated to  $VO_{2peak}$ , muscle strength, and quality of life. In all analyses a  $P < 0.05$  was considered statistically significant.

## RESULTS

Forty-two patients were eligible for the study, 24 of whom (57.1%) were willing to participate. One patient was excluded because of pulmonary comorbidities. Thus, 23 patients were included in the study (*Figure 1*); 10 boys and 13 girls, with a mean age of 12.7 years (range 8.6 – 17.9 years) (*Table 1*).

Thirteen patients (56.5%) had idiopathic uveitis and the other 10 patients (43.5%) had JIA-associated uveitis. Patients with JIA had no clinically important systemic disease activity at the time of study participation (median PGA 0.0, range 0.0 – 0.5).



At the time of study participation 20 patients (87.0%) were in remission on medication with regard to their uveitis. Three patients, 2 with JIA-uveitis and 1 with idiopathic uveitis, had mild uveitis activity. Eighteen patients (78.6%) used eye drops, 14 (60.9%) used systemic medication, 13 of whom used methotrexate (MTX) (Table 1). Nineteen patients (82.6%) had experienced complications of the uveitis (Table 2). Three patients experienced visual loss due to the uveitis, two of whom (8.7%) had unilateral visual impairment and one (4.3%) unilateral blindness. Because of the complications, 9 patients (39.1% of total study population) had undergone surgery; seven of whom (30.4% of total study population) had needed re-surgery (Table 2).

Mean weight and body mass index of the patients were statistically significantly higher when compared to the reference population (Table 1, Figure 2). Nine patients had higher BMI than the reference population, three of whom (13.0%) were obese and six were (26.1%) overweight. Patients with JIA-associated uveitis had a significantly higher BMI z-score than patients with idiopathic uveitis (z-score 1.26 vs 0.22,  $p=0.02$ ).

At the cardiopulmonary exercise test, patients reached a mean peak heart rate ( $HR_{max}$ ) of 191 ( $\pm 11$ ) beats per minute. At maximal exertion, four patients did not reach a heart rate of  $> 180$  beats per minute, but all patients reached a respiratory exchange ratio of more than 1.0, meaning that the exercise is intense because carbon dioxide ( $CO_2$ ) production by the working muscles becomes greater and more of the

inhaled oxygen ( $O_2$ ) gets used rather than being expelled. Median  $VO_{2peak}$  was comparable to  $VO_{2peak}$  of healthy children. Mean  $VO_{2peak}$  per kilogram bodyweight, median  $W_{peak}$ , and mean  $W_{peak}$  per kilogram bodyweight were all significantly lower than the reference value of healthy children ( $p<.05$ ) (Table 1, Figure 2).

All patients had a normal general muscle power (MRC-scale 5). However, in comparison to healthy controls maximal isometric muscle strength was





Figure 1. Patient selection

significantly reduced in patients ( $p < .01$ ) (Figure 2). There was no difference in physical fitness ( $VO_{2peak}$ ,  $W_{peak}$ , and muscle strength) between patients with JIA-associated uveitis and patients with idiopathic uveitis.

Measurement of physical activity by the accelerometer was valid in 21 children (91.3%). Patients were physically active during 182 (light) and 36 minutes (moderate-to-vigorously) per day, respectively. This is significantly lower than in healthy Canadian children ( $p < 0.001$ ) (Table 1)<sup>30</sup>. There was no difference in the amount of moderate-to-vigorous physical activity (MVPA) between patients with JIA-associated uveitis and patients with idiopathic uveitis.

Patients reported a normal functional ability (Table 1) and a normal HR-QoL. In contrast, parents indicated that their children had a lower quality of life compared to a reference group of parents of healthy children (Table 1). The same was seen with fatigue. Children with uveitis did not experience more fatigue than healthy children, but their parents judged their children were more fatigued compared to parents of healthy children. There was no correlation between patient reported and parent reported fatigue and between physical activity and fatigue scores. Patient and parent scores on HR-QoL and fatigue did not differ between patients with JIA-associated and idiopathic uveitis.



**Figure 2. Z-scores.** The z-score represents the amount of standard deviations the value differs from the age and gender specific reference value. Values are presented as mean with 95% confidence interval. Weight = weight for age, BMI = body mass index,  $VO_{2peak}$  = oxygen consumption at peak exercise,  $VO_{2peak}/kg$  = oxygen consumption per kg bodyweight,  $W_{peak}$  = peak work rate,  $W_{peak}/kg$  = peak work rate per kg bodyweight, Muscle strength = the sum of biceps, triceps, iliopsoas, and quadriceps muscles divided by eight as measured by hand-held dynamometry. \* Significant at  $p < 0.05$  (see Table 1)

**Table 1.** Patient characteristics and outcome measurements compared to reference values

	Number (%)	Mean ( $\pm$ SD) / Median (range)	Reference value	Z-score	Sig.
Age (yrs)		12.7 ( $\pm$ 2.7)			
Male	10 (43.5%)				
Female	13 (56.5%)				
<b>Anthropometrics</b>					
Length (cm)		156.7 ( $\pm$ 17.5)	AGD <sup>23</sup>	-0.19	p = 0.46
Weight (kg)		50.3 ( $\pm$ 17.7)	AGD <sup>23</sup>	0.58	p = 0.02
BMI		19.9 ( $\pm$ 4.0)	AGD <sup>23</sup>	0.67	p = 0.02
<b>Underlying systemic disease</b>					
juvenile idiopathic arthritis (JIA)	10				
PGA JIA activity	0				
<b>Uveitis<sup>a</sup></b>					
Idiopathic	13 (56.5%)				
JIA associated	10 (43.5%)				
Time since diagnosis (yrs)		5.88 (1.28 – 12.71)			
Remission duration (yrs) <sup>b</sup>		2.09 (0.17 – 8.35)			
Duration of active disease (yrs)		3.19 (0.55 – 11.91)			
Active disease (uveitis)	3 (13%)				
<b>Treatment<sup>c</sup></b>					
Local medication	18 (78.3%)				
Steroids	17 (73.9%)				
Anti-glaucoma	10 (43.5%)				
Mydriatics	1 (4.3%)				
Systemic medication	14 (60.9%)				
Steroids	1 (4.3%)				
MTX	13 (56.5%)				
Biological	7 (30.4%)				
<b>Physical fitness</b>					
VO <sub>2peak</sub> (l/min)		2.1 ( $\pm$ 0.84)	AGD <sup>44</sup>	-0.40	p = 0.11
VO <sub>2peak</sub> /kg (l/min/kg)		41.3 ( $\pm$ 8.1)	AGD <sup>44</sup>	-0.47	p = 0.07
W <sub>peak</sub> (Watt)		163 ( $\pm$ 65.5)	AGD <sup>44</sup>	-0.49	p = 0.04
W <sub>peak</sub> /kg (Watt/kg)		3.3 ( $\pm$ 0.6)	AGD <sup>44</sup>	-0.40	p = 0.05
HDD (Newton)		200.3 ( $\pm$ 68.2)	AGD <sup>46</sup>	-0.58	p = 0.001
<b>Questionnaires</b>					
Functional ability		0.22 (0 – 1.44)	0.20 <sup>51</sup>		p = 0.15
HR-QoL Child		84.2 ( $\pm$ 10.0)	83.91 <sup>50,51</sup>		p = 0.76
HR-QoL Parent		77.0 ( $\pm$ 11.7)	82.29		p = 0.04
Fatigue Child		82.9 ( $\pm$ 12.1)	80.49 <sup>54</sup>		p = 0.25
Fatigue Parent		72.0 ( $\pm$ 18.0)	89.63		p < 0.001
<b>Physical activity (N=21)<sup>d</sup></b>					
Light physical activity (min)		182 ( $\pm$ 75)	256 <sup>49</sup>		p < 0.001
MVPA (min)		36 ( $\pm$ 16)	54 <sup>49</sup>		p < 0.001

SD = standard deviation, AGD = age and gender dependent, yrs = years, min= minutes, BMI = body mass index, PGA = physician global assessment VO<sub>2peak</sub> = oxygen consumption at peak exercise, VO<sub>2peak</sub>/kg = peak oxygen consumption per kg bodyweight, W<sub>peak</sub> = peak work rate, W<sub>peak</sub>/kg = peak work rate per kg bodyweight, HDD = hand held dynamometry, MVPA = moderate-to-vigorous physical activity, HR-QoL = health related quality of life. <sup>a</sup> See Table 2 for further specifications. <sup>b</sup> Remission on medication. <sup>c</sup> Because some patients had more than one medication, the cumulative percentages can be different from the total percentages. <sup>d</sup> In 2 patients the measurement of physical activity was invalid.

Table 2. Ocular features

	Number of Patients (N=23)	Percentage	Median	Range
<b>Uveitis localization</b>				
Anterior	15	65.2 %		
Intermediate	4	17.4 %		
Posterior	0	—		
Panuveitis	4	17.4 %		
<b>Bilateral disease</b>	16	69.6%		
<b>Visual acuity (LogMAR*)</b>				
Worse eye			0.05	-0.08 – 2.48
Better eye			0.00	-0.08 – 0.22
Unilateral impairment**	2	8.7%		
Unilateral blindness**	1	4.3%		
<b>Complications**</b>				
Cataract	13	56.5%		
Glaucoma	13	56.5%		
Posterior synechiae	10	43.5%		
Band keratopathy	5	21.7%		
Amblyopia	1	4.3%		
<b>Surgery***</b>				
Cataract extraction	8	34.8%		
Baerveldt-implantation (anti-glaucoma treatment)	8	34.8%		
Re-surgery	7	30.4%		

LogMAR= Logarithm of the Minimum Angle of Resolution. \* A lower LogMAR visual acuity score corresponds to higher Snellen visual acuity and vice versa. \*\* Visual impairment was defined as a visual acuity  $\geq 0.05$  (LogMAR  $\leq 1.30$ ) and  $< 0.3$  (LogMAR  $> 0.50$ ), blindness was defined as a visual acuity less than 0.01 (or LogMAR  $> 1.3$ ) or a visual field  $\leq 10^\circ$  <sup>40</sup>. \*\*\* Because some patients had more than one complication, surgery or medication, the cumulative percentages can be different from the total percentages.

Table 3. Correlations

	VO <sub>2</sub> peak*		HDD*		HR-QoL child		HR-QoL parent	
	P	p	r	p	r	p	r	p
Gender	-0.15	0.51	-0.13	0.55	-0.25	0.25	-0.06	0.79
Age	0.37	0.09	0.51	<b>0.01</b>	0.40	0.06	0.30	0.17
Duration of active disease	-0.28	0.19	-0.12	0.59	-0.16	0.47	-0.63	<b>0.001</b>
systemic medication	-0.28	0.20	-0.05	0.81	-0.07	0.75	-0.21	0.33
BMI*	0.30	0.17	0.69	<b>&lt; 0.001</b>	0.38	0.08	-0.11	0.63
HDD*	0.53	<b>0.01</b>			0.55	<b>0.01</b>	0.19	0.38
VO <sub>2</sub> peak*			0.53	<b>0.01</b>	0.35	0.10	0.26	0.24
MVPA	0.05	0.85	-0.08	0.74	0.04	0.86	0.24	0.32
DI					-0.64	<b>0.001</b>	-0.10	0.64
HR-QoL child	0.35	0.10					0.06	0.78
HR-QoL parent	0.26	0.24			0.06	0.78		
Fatigue child	0.36	0.09	0.46	<b>0.03</b>	0.83	<b>&lt; 0.001</b>	-0.21	0.34
Fatigue parent	0.33	0.12	0.21	0.33	-0.04	0.85	0.73	<b>&lt; 0.001</b>

Values presented as Spearman correlation (P) or Pearson correlation (r) and statistical significance (p). \* Z-scores. Abbreviations: BMI = body mass index, HDD = hand-held dynamometry measurements for muscle strength, VO<sub>2</sub>peak= peak oxygen consumption (l/min), Wpeak = peak work rate (Watt), MVPA = moderate-to-vigorous physical activity, DI = disability index, HR-QoL = health related quality of life.

Correlations are shown in Table 3. The correlation-coefficient between  $VO_{2peak}$  and  $W_{peak}$  was 0.94 ( $P = < 0.001$ ),  $VO_{2peak}$  was therefore used and interpreted as a measure for exercise capacity. Muscle strength (HDD) was correlated with higher  $VO_{2peak}$ . Older age and higher BMI were correlated with higher muscle strength. Higher child reported HR-QoL was correlated with higher muscle strength and less fatigue (higher score means less fatigue). Higher disability was correlated with lower HR-QoL. Longer duration of active disease was correlated with lower HR-QoL reported by the parents about their child. Less fatigue was associated with a higher HR-QoL reported by the parents about their children.

## DISCUSSION

Patients with uveitis have higher BMI compared to healthy children, they are at risk for reduced physical fitness levels as indicated by a lower aerobic exercise capacity and reduced muscle strength when compared to the healthy pediatric population. Also, children with uveitis are less physically active (PA), and their parents report a lower quality of life (HR-QoL) and more fatigue for their children when compared to parents of healthy children. In contrast, the children themselves report a normal HR-QoL and fatigue. The children with JIA-uveitis have a statistically significantly higher BMI than the children with idiopathic uveitis. No differences are found between JIA and idiopathic uveitis patients in physical fitness levels.

We found a significantly higher percentage of overweight (26%) and obese (14%) patients compared to the Dutch population, 13-15% and 2.2%, respectively. In patients with JIA-uveitis BMI was significantly higher compared to non JIA uveitis. Corticosteroids are a well-known cause of weight gain<sup>12</sup>, however in our study only one patient used low dose (5 mg) systemic corticosteroids and most of the patients had not used systemic steroids for a long period of time. In JIA, contradictory results concerning obesity have been found and the cause has not been revealed yet<sup>55,56</sup>. A possible explanation is a more sedentary lifestyle which we also found in this study. There are indications that obesity in JIA can result in higher inflammatory markers and an increased risk of atherosclerosis<sup>11, 12, 57</sup>. It is reasonable to assume that this risk is comparable in patients with uveitis, so healthcare professionals and carers should be aware of weight gain in patients with uveitis.

Children with uveitis have lower aerobic exercise capacity levels than their healthy peers, but relatively well preserved levels when compared to children with other chronic conditions<sup>5,6</sup>. Interestingly, we found no differences in aerobic exercise capacity between JIA and idiopathic uveitis patients. The arthritis of the ten patients with JIA uveitis was in remission. It is known that the aerobic exercise capacity in patients with JIA does not restore after remission has been

reached<sup>9</sup>. We assume that comparable underlying mechanisms could play a causative role in uveitis but their nature has not yet been revealed. The general assumption is that reduced levels of aerobic fitness are caused by a combination of disease-related pathophysiology, treatment (e.g., medication), hypo-activity, and deconditioning<sup>5, 11, 12</sup>.

Patients with uveitis have decreased muscle strength that is possibly caused by the same combination of mechanisms that are responsible for the reduced exercise capacity. From the literature it is known that low exercise capacity, decreased muscle strength, the inflammation itself, circulating cytokines and the use of systemic corticosteroids are correlated with an increased risk of cardiovascular diseases<sup>11, 12, 58, 59</sup>. In children with uveitis, these factors are present. Therefore, physicians should be alert and try to eliminate extra cardiovascular risk factors.

Our patients report 32 minutes of moderate-to-vigorous physical activity (MVPA) per day which is considerably less than the 60 minutes of daily MVPA as recommended by the WHO and the MVPA of the reference group<sup>49, 60</sup>. Similar results have been found for adolescents with JIA<sup>8, 9</sup>. Hypoactive children are often at greater risk of preventable health problems, such as obesity and cardio-metabolic diseases<sup>5, 57</sup>. Cardiovascular health in children can be improved by sufficient physical activity (PA) and physical fitness<sup>61</sup>, whereas PA also has a beneficial effect on HR-QoL<sup>4</sup>. In several auto-immune diseases, PA has been shown to be safe, to improve HR-QoL and to reduce fatigue<sup>4</sup>.

The parents of our patients score a lower quality of life and higher levels of fatigue for their children than parents of healthy children, whereas the children themselves report outcomes comparable to those of their healthy peers on both questionnaires. This difference is probably due the proxy-problem, a known variation in patient and parent-report<sup>62</sup>. In the measurement of quality of life, parents tend to score a lower quality of life for their chronically ill children than the children themselves. This is possibly due to the differences in adaptation to a chronic disease in child and parent. Parents are possibly more aware of the health risks and have a broader perspective than children<sup>62, 63</sup>. Also, it is likely that the parent-reported HR-QoL and fatigue are influenced by their frequent visits to the hospital and their efforts associated with the medical treatment of their child.

The positive correlations in our study between exercise capacity, muscle strength and BMI are not supported in the literature<sup>65</sup>. Also, the reported loss of HR-QoL<sup>52, 66</sup> and increase in fatigue in children with overweight is not found in our results. We cannot explain these findings. Perhaps the significantly lower PA combined with adaptation in coping strategies by the children are responsible for these contradictory results. We did not investigate body composition, so we

cannot comment on the influence of differences between muscle and fat mass on measured BMI in relation the muscle strength and exercise capacity. The negative correlations between lower HR-QoL (reported by children) and loss of functional ability and between lower HR-QoL (reported by parents) and longer disease duration are in line with the literature<sup>33, 51 – 54, 67</sup>.

### Limitations of the study

We performed this study as a pilot with a small number of patients. Furthermore, this study is cross sectional and most patients were in disease remission. Patients in other phases of the disease may have different results. Also, there is an unknown selection bias, because not all eligible patients participated. Another possible bias is that this study was conducted in a tertiary center. In the Netherlands, children with uveitis who require systemic therapy are treated and managed in tertiary (in most cases university) centers. The results thus do not represent the total spectrum of pediatric non-infectious uveitis and the results and conclusions should be interpreted in this way.

### Clinical implications

We recommend that clinicians discuss the importance of sufficient levels of physical fitness and PA during outpatient visits with patients and their parents. Also, close monitoring of body weight should be performed and the prevention of overweight should be a treatment goal.

## CONCLUSION

This pilot-study investigated the physical and psychosocial consequences of uveitis in childhood. We showed that patients with non-infectious uveitis are at risk of developing cardiovascular risk factors early in life. Children with uveitis have a higher BMI, lower cardio-respiratory fitness and are less physically active when compared to healthy peers. Furthermore, their parents report a lower quality of life and more fatigue for their children compared to the parents of healthy children. It remains undecided whether this can be attributed to the systemic treatment or the inflammatory disease, since children with idiopathic non-infectious uveitis had similar test results as children with JIA-uveitis. Clinicians should discuss the importance of sufficient levels of physical fitness and PA with patients and their parents during outpatient visits. With the current knowledge and the results of our study we believe we can contribute to the optimisation of the treatment for children with uveitis. Treatment of paediatric uveitis should be aimed at improving the physical and psychosocial health and reducing cardiovascular risk factors in this vulnerable group of patients in addition to maintaining and preserving vision.

## REFERENCES

1. Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in Children: Population-based Study in Finland. *Acta Ophthalmol Scand.* 2000;78(1):84-88.
2. Zierhut M, Doycheva D, Biester S, Stübiger N, Kümmerle-Deschner J, Deuter C. Therapy of Uveitis in Children. *Int Ophthalmol Clin.* 2008;48(3):131-152.
3. Mehta PJ, Alexander JL, Sen HN. Pediatric uveitis: New and future treatments. *Curr Opin Ophthalmol.* 2013;24(5):453-462.
4. Sharif K, Watah A, Bragazzi N.L, Lichtbroun M, Amital H, Shoenfeld Y. Physical activity and autoimmune diseases: Get moving and manage the disease. *Autoimmun Rev.* 2018; 17( 1), 53-72.
5. Takken T, Bongers BC, van Brussel M, Haapala EA, Hulzebos EHJ. Cardiopulmonary Exercise Testing in Pediatrics. *Ann Am Thorac Soc.* 2017; Supplement 1, S123-S128.
6. van Brussel M, van der Net J, Hulzebos E, Helders PJ, Takken T. The Utrecht approach to exercise in chronic childhood conditions: the decade in review. *Pediatr Phys Ther.* 2011; 23, (1): 2-14.
7. Gualano B, Bonfa E, Pereira RMR, Silva CA. Physical activity for paediatric rheumatic diseases: standing up against old paradigms. *Nat Rev Rheumatol.* 2017;13, (6): 368-379.
8. Lelieveld OT, Armbrust W, van Leeuwen M a, et al. Physical Activity in Adolescents with Juvenile Idiopathic Arthritis. *Arthritis Rheum.* 2008;59(10):1379-1384.
9. van Brussel M, Lelieveld OTHM, van der Net J, Engelbert RHH, Helders PJM, Takken T. Aerobic and Anaerobic Exercise Capacity in Children with Juvenile Idiopathic Arthritis. *Arthritis Rheum.* 2007;57(6):891-897.
10. Ploeger HE, Takken T, Wilk B, et al. Exercise Capacity in Pediatric Patients with Inflammatory Bowel Disease. *J Pediatr.* 2011;158(5):814-819.
11. Roubenoff R. Exercise and Inflammatory Disease. *Arthritis Care Res (Hoboken).* 2003;49(2):263-.
12. Gupta Y, Gupta A. Glucocorticoid-induced Myopathy: Pathophysiology, Diagnosis, and Treatment. *Indian J Endocrinol Metab.* 2013;17(5):913-916.
13. Angeles-Han ST, Rabinovich CE. Uveitis in children. *Curr Opin Rheumatol.* 2016 Sep;28(5): 544-9.
14. Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and Auto-inflammatory Mechanisms in Uveitis. *Semin Immunopathol.* 2014;36(5):581-594.
15. Coulson EJ, Ng W-F, Goff I, Foster HE. Cardiovascular Risk in Juvenile Idiopathic Arthritis. *Rheumatology.* 2013;52(7):1163-1171.
16. Barsalou J, Bradley TJ, Silverman ED. Cardiovascular Risk in Pediatric-onset Rheumatological Diseases. *Arthritis Res Ther.* 2013;15:212.
17. Libby P. Role of Inflammation in Atherosclerosis Associated with Rheumatoid Arthritis. *Am J Med.* 2008;121(10 Suppl 1):S21-S31.
18. Dana MR, Merayo-Llodes J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. *Ophthalmology.* 1997;104(2):236-244.
19. Kalinina Ayuso V, Makhotkina N, van Tent-Hoeve M, de Groot-Mijnes JD, Wulfraat NM, Rothova A, de Boer JH. Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown. *Surv.Ophthalmol.* 2014;59(5):517-531.
20. Haasnoot AM, Kuiper JJ, Hiddingh S, Schellekens PA, de Jager W, Imhof SM, Radstake TR, de Boer JH. Ocular Fluid Analysis in Children Reveals Interleukin-29/Interferon-lambda1 as a Biomarker for Juvenile Idiopathic Arthritis-Associated Uveitis. *Arthritis Rheumatol.* 2016;68(7):1769-1779.
21. Haasnoot AJ, van Tent-Hoeve M, Wulfraat NM, Schalijs-Delfos NE, Los LI, Armbrust W, Zuihoff NP, de Boer JH. Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis. *Am J Ophthalmol.* 2015 Feb;159(2):372-7.



22. Pelegrin L, Casaroli-Marano R, Anton J, Garcia de Vicuna MC, Molina-Prat N, Ignacio Arostegui J, Yague J, Rios J, Adan A. Predictive value of selected biomarkers, polymorphisms, and clinical features for oligoarticular juvenile idiopathic arthritis-associated uveitis. *Ocul Immunol Inflamm.* 2014;22(3):208-212.
23. Walscheid K, Heiligenhaus A, Holzinger D, Roth J, Heinz C, Tappeiner C, Kasper M, Foell D. Elevated S100A8/A9 and S100A12 Serum Levels Reflect Intraocular Inflammation in Juvenile Idiopathic Arthritis-Associated Uveitis: Results From a Pilot Study. *Invest Ophthalmol Vis Sci.* 2015 Dec;56(13):7653-6.
24. Haasnoot AJW, Schilham MW, Kamphuis S, Hissink Muller PCE, Heiligenhaus A, Foell D, Minden K, Ophoff RA, Radstake TRDJ, Den Hollander AI, Reinards THCM, Hiddingh S, Schalijs-Delfos NE, Hoppenreijns EPAH, van Rossum MAJ, Wouters C, Saurenmann RK, van den Berg JM, Wulffraat NM; ICON-JIA Study Group, Ten Cate R, de Boer JH, Pulit SL, Kuiper JJW. Identification of an Amino Acid Motif in HLA-DR $\beta$ 1 That Distinguishes Uveitis in Patients With Juvenile Idiopathic Arthritis. *Arthritis Rheumatol.* 2018 Jul;70(7):1155-1165.
25. Gedalia A, Shetty AK. Chronic Steroid and Immunosuppressant Therapy in Children. *Pediatr Rev.* 2004;25(12):425-434.
26. Angeles-Han S, Griffin K, Lehman T, Rutledge J, Lyman S, Nguyen J, et al. The importance of visual function in the quality of life of children with uveitis. *J Am Assoc Pediatr Ophthalmol Strabismus.* 2010;12(2):163-8.
27. Angeles-Han ST. Quality-of-life metrics in pediatric uveitis. *Int Ophthalmol Clin.* 2015;55(2):93-101
28. Angeles-Han ST, Griffin KW, Harrison MJ, Lehman TJ, Leong T, Robb RR, Shainberg M, Ponder L, Lenhart P, Hutchinson A, Srivastava SK, Prahald S, Lambert SR, Drews-Botsch C. Development of a vision-related quality of life instrument for children ages 8-18 years for use in juvenile idiopathic arthritis-associated uveitis. *Arthritis Care.Res.(Hoboken)*, 2011;63(9)1254-1261.
29. Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Rouster-Stevens K, Vogler LB, Lambert SR, Drews-Botsch C, Prahald S. Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis. *Pediatr Rheumatol Online J.* 2015 Jun 2;13:19.
30. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. *Arch Ophthalmol.* 2001 Jun;119(6):841-9
31. Hoeksema L, Los LI. Vision-related quality of life in herpetic anterior uveitis patients. *PLoS One.* 2014 Jan 2;9(1)
32. Haasnoot AJW, Sint Jago NFM, Tekstra J, de Boer JH. Impact of Uveitis on Quality of Life in Adult Patients With Juvenile Idiopathic Arthritis. *Arthritis Care Res (Hoboken).* 2017 dec;69(12):1895-1902
33. Miserocchi E, Modorati G, Mosconi P, Colucci A, Bandello F. Quality of Life in Patients with Uveitis on Chronic Systemic Immunosuppressive Treatment. *Ocul Immunol Inflamm.* 2010;18(4):297-304.
34. Maca SM, Amirian A, Prause C, Gruber K, Mejdoubi L, Barisani-Asenbauer T. Understanding the Impact of Uveitis on Health-related Quality of Life in Adolescents. *Acta Ophthalmol.* 2013;91(3):219-224.
35. Petrina Tan, Yan Tong Koh, Poh Ying Wong & Stephen C. Teoh. Evaluation of the Impact of Uveitis on Visual-related Quality of Life. *Ocular Immunology and Inflammation.* 2012;20(6):453-459.
36. Reichert FF, Barros AJD, Domingues MR, Hallal PC. The Role of Perceived Personal Barriers to Engagement in Leisure-time Physical Activity. *Am J Public Health.* 2007;97(3):515-519.
37. Armbrust W, Lelieveld OH, Tuinstra J, Wulffraat NM, Bos GJ, Cappon J, van Rossum MA, Sauer PJ, Hagedoorn M. Fatigue in patients with Juvenile Idiopathic Arthritis: relationship to perceived health, physical health, self-efficacy, and participation. *Pediatr Rheumatol Online J.* 2016 Dec 6;14(1):65.

38. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol*. 2005 Sep;140(3):509-16.
39. Holladay JT. Proper method for calculating average visual acuity. *J Refract Surg*. 1997 Jul-Aug;13(4):388-91.
40. World Health Organization. Universal eye health: a global action plan 2014–2019. [Internet].p 7-8.[cited 2018 July 8<sup>th</sup>] Available from: [http://www.who.int/blindness/AP2014\\_19\\_English.pdf?ua=1](http://www.who.int/blindness/AP2014_19_English.pdf?ua=1)
41. TNO. Vijfde Landelijke Groeistudie: Groeidiagrammen [Internet]. 2010. [cited 2018 July 8<sup>th</sup>] Oct 20] Available from: <https://www.tno.nl/nl/aandachtsgebieden/gezond-leven/prevention-work-health/lang-gezond-en-actief-leven/pdf-groeidiagrammen/>
42. Cole TJ, Lobstein T. Extended International (IOTF) Body Mass Index Cut-offs for Thinness, Overweight and Obesity. *Pediatr Obes*. 2012;7(4):284-294.
43. Godfrey S. Methods of measuring the response to exercise in children. Exercise testing in children: applications in health and disease. London: W.B. Saunders Company Ltd; 1974. p. 12–41.
44. Bongers BC, Hulzebos EHJ, van Brussel M, Takken T. Pediatric Norms for Cardiopulmonary Exercise Testing: In Relation to Gender and Age. 's-Hertogenbosch Uitg BOXPRESS. 2012:129.
45. Compston A. From the archive: Aids to the Investigation of Peripheral Nerve Injuries: Medical Research Council 1942. *Brain*. 2010 Sep 29;133(10):2838–44.
46. Beenakker E a, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. *Neuromuscul Disord*. 2001 Jul;11(5):441–6.
47. Puyau MR, Adolph AL, Vohra FA, Zakeri I, Butte NF. Prediction of Activity Energy Expenditure Using Accelerometers in Children. *Med Sci Sports Exerc*. 2004;36(9):1625-1631.
48. Bratteby L, Sandhagen B, Fan H, Samuelson G. A 7-day activity diary for assessment of daily energy expenditure validated by the doubly labelled water method in adolescents. *Eur J Clin Nutr*. 1997;51:585–91.
49. Colley RC, Garriguet D, Janssen I, Craig CL, Clarke J, Tremblay MS. Physical activity of Canadian Children and Youth: Accelerometer results from the 2007 to 2009 Canadian Health Measures Survey. *Heal Reports*. 2011;22(1):1-9. [cited 2018 July 8<sup>th</sup>]. <http://www.statcan.gc.ca/pub/82-003-x/2011001/article/11396-eng.htm>
50. Wulffraat N, Net JJ Van Der, Ruperto N, et al. The Dutch Version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol*. 2001;19(Suppl 23):S111-S115.
51. Ouwkerk JW, van Pelt PA, Takken T, Helders PJ, Net Jv. Evaluating score distributions in the revised Dutch version of the Childhood Health Assessment Questionnaire. *Pediatr Rheumatol Online J*. 2008 Sep 11;6:14.
52. Varni JW, Burwinkle TM, Seid M. The PedsQL™ 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity. *Ambul Pediatr*. 2003;3(6):329-341.
53. Varni JW, Burwinkle TM, Szer IS. The PedsQL™ Multidimensional Fatigue Scale in pediatric rheumatology: reliability and validity. *J Rheumatol*. 2004;31(12):2494–500.
54. Gordijn M, Cremers EM, Kaspers GJ, Gemke RJ. Fatigue in children: reliability and validity of the Dutch PedsQL™ Multidimensional Fatigue Scale. *Qual Life Res*. 2011 Sep;20(7):1103-8.

55. Pelajo CF, Lopez-Benitez JM, Miller LC. Obesity and disease activity in juvenile idiopathic arthritis. *Pediatr Rheumatol Online J* 2012;10:3.
56. Schenck S1, Niewerth M, Sengler C, Trauzeddel R, Thon A, Minden K, Klotsche J. Prevalence of overweight in children and adolescents with juvenile idiopathic arthritis. *Scand J Rheumatol*. 2015;44(4):288-95.
57. Zoico E, Roubenoff R. The Role of Cytokines in Regulating Protein Metabolism and Muscle Function. *Nutr Rev*. 2002;60(2):39-51.
58. Carnethon M, Gidding S, Nehgme R, Sidney S, Jacobs D, Liu K. Cardiorespiratory Fitness in Young Adulthood and the Development of Cardiovascular Diseases Risk Factors. *JAMA*. 2003;290(23):3092-3100
59. Steene-Johannessen J, Anderssen S a, Kolle E, Andersen LB. Low muscle fitness is associated with metabolic risk in youth. *Med Sci Sports Exerc*. 2009 Jul;41(7):1361-7.
60. WorldHealthOrganization. Global Recommendations on Physical Activity for Health.; 2010. [cited 2018 july 8<sup>th</sup>]. Available at: <http://www.who.int/dietphysicalactivity/publications/9789241599979/en/>.
61. Strong WB, Malina RM, Blimkie CJR, et al. Evidence Based Physical Activity for School-age Youth. *J Pediatr*. 2005;146(6):732-737.
62. Sattoe JNT, van Staa A, Moll HA. The Proxy Problem Anatomized: Child-Parent Disagreement in Health Related Quality of Life Reports of Chronically Ill Adolescents. *Health Qual Life Outcomes*. 2012;10(1):10.
63. Jardine J, Glinianaia S V, McConachie H, Embleton ND, Rankin J. Self-Reported Quality of Life of Young Children With Conditions From Early Infancy: A Systematic Review. *Pediatrics*. 2014;134(4):e1129-e1148.
64. Schönbeck Y, Talma H, van Dommelen P, et al. Increase in prevalence of overweight in Dutch children and adolescents: a comparison of nationwide growth studies in 1980, 1997 and 2009. *PLoS One*. 2011;6(11):e27608.
65. Rauner A, Mess F, Woll A. The Relationship Between Physical Activity, Physical Fitness and Overweight in Adolescents: a Systematic Review of Studies Published in or after 2000. *BMC Pediatr*. 2013;13(1):19.
66. Keating CL, Moodie ML, Swinburn B a. The health-related quality of life of overweight and obese adolescents: a study measuring body mass index and adolescent-reported perceptions. *Int J Pediatr Obes*. 2011 Oct;6(5-6):434-41.
67. Haverman L, Grootenhuis MA, van den Berg JM, van Veenendaal M, Dolman KM, Swart JF, Kuijpers TW, van Rossum MA. Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a Web-based survey. *Arthritis Care Res (Hoboken)*. 2012 May;64(5):694-703



